Oxford Biomedica
OXB · Main Market · Health Care · mcap £631m · 514.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 02 Oct 26 | Grant of Award
Chief Operating Officer granted nil-cost share options over 94,156 ordinary shares under LTIP 2026. |
+6.9% | |
| 22 Sep 26 | Results | Half-year Results
H1 2026 revenue grew 10% to £80.2m; 17 new clients signed, Durham NC site online, FY26 guidance reiterated. |
+6.0% |
| 07 Aug 26 | Half Year Trading Update and Notice of Results
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. |
−14.6% | |
| 16 Jul 26 | Manufacturing agreement with Plowshare Therapies
Oxford Biomedica selected as manufacturing partner for Plowshare Therapies' AAV gene therapy programme. |
+0.9% | |
| 02 Jun 26 | OXB Capital Markets Event
Oxford Biomedica hosts capital markets event outlining strategy and 2030 revenue target of approximately £500m. |
−6.7% | |
| 27 May 26 | Director Declaration
Oxford, UK - 27 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that pursuant to UK Listing Rules 6.4.9R, Peter Soelkner, Vice Chair and Independe |
−0.5% | |
| 13 Apr 26 | Launch of viral vector fast-track offering
Oxford Biomedica launches fast-track offering for AAV and lentiviral vector manufacturing, accelerating timelines to GMP by up to nine months. |
+1.1% | |
| 30 Mar 26 | 2026 Annual General Meeting notification
Oxford Biomedica notifies shareholders of 2026 Annual General Meeting scheduled for 7 May 2026. |
−1.8% | |
| 26 Mar 26 | Results | Final Results
FY25 revenues grew 33% to £170.9m with Operating EBITDA profitability of £8.1m; FY26 guidance £220-240m revenue with 10% EBITDA margin. |
−5.1% |
| 18 Mar 26 | Licensing agreement with VVMF
OXB licenses its AAV and LV viral vector platforms to Australian CDMO VVMF under five-year agreement. |
+1.1% | |
| 03 Mar 26 | Capital Markets Day and investor conferences
OXB announces date for Capital Markets Day and participation in upcoming investor conferences |
−2.9% | |
| 25 Feb 26 | Response to Rule 2.8 Announcement
EQT confirms it will not proceed with possible offer for OXB; all four proposals were rejected by the Board. |
−7.5% | |
| 25 Feb 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
−7.5% | |
| 25 Feb 26 | Rule 2.8 Announcement
EQT confirms it is not intending to make an offer for Oxford Biomedica. |
−7.5% | |
| 24 Feb 26 | Full year Trading Update and Notice of Results
Full year Trading Update and Notice of Results |
−11.8% | |
| 11 Feb 26 | Extension of PUSU Deadline
EQT given extended deadline of 25 February 2026 to announce firm offer or walk away from possible acquisition. |
−1.2% | |
| 04 Feb 26 | Multi-year supply agreement with BMS
OXB signs multi-year commercial supply agreement with BMS for lentiviral vectors for CAR-T programmes. |
+1.0% | |
| 14 Jan 26 | Disclosure Table
The following are today's changes to the Disclosure Table: |
+8.8% | |
| 14 Jan 26 | Response to press speculation
EQT has made unsolicited approach for possible cash offer; Board in preliminary discussions to explore terms. |
+8.8% | |
| 29 Oct 25 | OXB honoured at 2025 CDMO Leadership Awards Europe
Oxford Biomedica named Champion in Cell & Gene Therapy category at 2025 CDMO Leadership Awards Europe. |
+2.2% | |
| 27 Oct 25 | OXB to participate in investor conferences
Oxford Biomedica to present at investor conferences in November 2025. |
+1.8% | |
| 20 Oct 25 | Board change | Directorate Change
Non-Executive Director Robert Ghenchev steps down following departure from Novo Holdings US. |
−2.2% |
| 07 Oct 25 | Acquisition of US viral vector facility
OXB acquires FDA-approved viral vector manufacturing facility in North Carolina from Resilience for $4.5 million. |
−1.7% |
Company filings. Not investment advice.